口服与静脉抗生素治疗骨折相关感染:POvIV随机临床试验
POvIV多中心随机试验纳入233例无骨髓炎影像证据的骨折相关感染患者,比较口服与静脉抗生素效果。主要结局为1年内手术干预次数,非劣效界值0.67。未调整mITT分析显示口服非劣于静脉,但调整PP分析未支持非劣效,事后调整mITT分析再次显示非劣效。深部手术部位感染复发呈现相似模式。
要点
- 口服抗生素在减少1年内手术干预次数方面非劣于静脉抗生素(未调整mITT分析)。
- 调整PP分析未支持非劣效,事后调整mITT分析支持非劣效,结果存在不确定性。
- 深部手术部位感染复发的治疗效应估计与主要结局模式相似。
核心结论
- 基于未调整mITT分析,口服抗生素在1年内手术干预次数方面非劣于静脉抗生素。
- 预设PP分析和事后调整mITT分析结果不完全一致,提示结论存在不确定性。
研究设计与样本
- 多中心前瞻性随机临床试验,在美国24个创伤中心开展。
- 纳入18至84岁骨折修复或关节融合固定后发生骨折相关感染且无骨髓炎影像证据的患者。
- 2013年3月至2018年9月入组,治疗后随访12个月,共233例患者。
主要发现
- 患者平均年龄46.0岁(SD 13.9),女性53例(22.7%)。
- 口服组和静脉组1年内平均手术干预次数分别为1.3次和1.1次。
- 未调整mITT分析中平均差异95%CI上限为0.59,低于预设非劣效界值0.67。
- 调整PP分析未支持再手术次数的非劣效性,事后调整mITT分析显示非劣效。
- 关键次要结局再感染的治疗效应估计与主要结局模式相似。
关键数值与推荐
- 主要结局为非劣效性检验,非劣效界值为0.67(手术干预次数平均差异)。
- 未调整mITT分析95%CI上限0.59<0.67,支持口服非劣于静脉。
临床怎么用
- 对于无骨髓炎影像证据的骨折相关感染,口服抗生素可作为静脉抗生素的替代选择。
- 临床决策需结合预设PP分析未支持非劣效的不确定性,个体化评估。
局限性
- 预设PP分析和事后调整mITT分析结果不一致,结论存在不确定性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Fracture-related infection (FRI) is a serious complication following fracture fixation surgery. Current treatment of FRIs entails debridement and 6 weeks of intravenous (IV) antibiotics. Lab data and retrospective clinical studies support use of oral antibiotics, which are less expensive and may have fewer complications than IV antibiotics. OBJECTIVE: To evaluate the effectiveness of treatment of FRI with oral vs IV antibiotics. DESIGN, SETTING, AND PARTICIPANTS: The POvIV multicenter, prospective randomized clinical trial was conducted across 24 trauma centers in the US among patients aged 18 to 84 years who had fracture repair or arthrodesis with fixation with implants and developed an FRI without radiographic evidence of osteomyelitis. Patients were enrolled between March 2013 and September 2018 and followed up for 12 months after hospitalization for treatment of their FRI. INTERVENTION: Oral vs IV antibiotics following FRI. MAIN OUTCOMES AND MEASURES: The primary outcome was number of surgical interventions, and the primary hypothesis was noninferiority of oral vs IV antibiotics with respect to the number of study injury-related surgical interventions by 1 year. Unadjusted modified intent-to-treat (mITT) and adjusted per-protocol (PP) analyses were prespecified. A post hoc adjusted mITT analysis was conducted to resolve discrepancies between the results of the prespecified mITT and PP analyses. Recurrence of a deep surgical site infection was a key secondary outcome. RESULTS: Among 233 total patients, mean (SD) age was 46.0 (13.9) years, and 53 patients were female (22.7%). The mean number of surgical interventions within 1 year was 1.3 and 1.1 for the oral and IV groups, respectively. The upper bound of the 95% confidence interval of the mean difference with unadjusted mITT analysis was 0.59, which was lower than the prespecified noninferiority margin of 0.67, indicating noninferiority of oral to IV antibiotics. Adjusted PP analysis did not support noninferiority of the number of reoperations. A post hoc adjusted mITT analysis also showed noninferiority. The treatment effects estimates for the key secondary outcome of reinfection showed a similar pattern as those for the primary outcome. CONCLUSIONS AND RELEVANCE: In this prospective randomized clinical trial, oral antibiotic treatment was noninferior to IV treatment with respect to the primary outcome of number of surgical interventions based on mITT analysis. However, there is some uncertainty in these findings based on preplanned and post hoc secondary analyses. A similar pattern of treatment effect estimates was observed for the secondary outcome of recurrence of infection. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01714596.
引用
- Obremskey WT, O'Toole RV, Morshed S, et al. Oral vs Intravenous Antibiotics for Fracture-Related Infections: The POvIV Randomized Clinical Trial. JAMA Surg. 2025. PMID: 39841468. doi:10.1001/jamasurg.2024.6439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。